South Korea · Delayed Price · Currency is KRW LabGenomics Statistics
Total Valuation
LabGenomics has a market cap or net worth of KRW 95.99 billion. The enterprise value is 93.47 billion.
| Market Cap | 95.99B |
| Enterprise Value | 93.47B |
Important Dates
The last earnings date was Friday, April 3, 2026.
| Earnings Date | Apr 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
LabGenomics has 74.24 million shares outstanding. The number of shares has increased by 0.47% in one year.
| Current Share Class | 74.24M |
| Shares Outstanding | 74.24M |
| Shares Change (YoY) | +0.47% |
| Shares Change (QoQ) | +0.05% |
| Owned by Insiders (%) | 0.53% |
| Owned by Institutions (%) | 5.76% |
| Float | 61.85M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.09 |
| PB Ratio | 0.64 |
| P/TBV Ratio | 1.29 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.45 |
| EV / Sales | 1.06 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -2.95 |
Financial Position
The company has a current ratio of 1.24, with a Debt / Equity ratio of 0.37.
| Current Ratio | 1.24 |
| Quick Ratio | 1.16 |
| Debt / Equity | 0.37 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.75 |
| Interest Coverage | -9.59 |
Financial Efficiency
Return on equity (ROE) is -35.18% and return on invested capital (ROIC) is -34.28%.
| Return on Equity (ROE) | -35.18% |
| Return on Assets (ROA) | -13.06% |
| Return on Invested Capital (ROIC) | -34.28% |
| Return on Capital Employed (ROCE) | -32.31% |
| Weighted Average Cost of Capital (WACC) | 6.09% |
| Revenue Per Employee | 620.85M |
| Profits Per Employee | -453.34M |
| Employee Count | 142 |
| Asset Turnover | 0.34 |
| Inventory Turnover | 18.02 |
Taxes
In the past 12 months, LabGenomics has paid 4.12 billion in taxes.
| Income Tax | 4.12B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -41.36% in the last 52 weeks. The beta is 0.12, so LabGenomics's price volatility has been lower than the market average.
| Beta (5Y) | 0.12 |
| 52-Week Price Change | -41.36% |
| 50-Day Moving Average | 1,547.90 |
| 200-Day Moving Average | 2,072.52 |
| Relative Strength Index (RSI) | 38.05 |
| Average Volume (20 Days) | 364,940 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, LabGenomics had revenue of KRW 88.16 billion and -64.37 billion in losses. Loss per share was -867.00.
| Revenue | 88.16B |
| Gross Profit | 29.37B |
| Operating Income | -54.92B |
| Pretax Income | -60.26B |
| Net Income | -64.37B |
| EBITDA | -44.61B |
| EBIT | -54.92B |
| Loss Per Share | -867.00 |
Balance Sheet
The company has 58.02 billion in cash and 55.50 billion in debt, with a net cash position of 2.52 billion or 33.94 per share.
| Cash & Cash Equivalents | 58.02B |
| Total Debt | 55.50B |
| Net Cash | 2.52B |
| Net Cash Per Share | 33.94 |
| Equity (Book Value) | 149.62B |
| Book Value Per Share | 2,014.33 |
| Working Capital | 14.32B |
Cash Flow
In the last 12 months, operating cash flow was -30.54 billion and capital expenditures -1.14 billion, giving a free cash flow of -31.67 billion.
| Operating Cash Flow | -30.54B |
| Capital Expenditures | -1.14B |
| Depreciation & Amortization | 10.31B |
| Net Borrowing | -2.07B |
| Free Cash Flow | -31.67B |
| FCF Per Share | -426.64 |
Margins
Gross margin is 33.32%, with operating and profit margins of -62.29% and -73.02%.
| Gross Margin | 33.32% |
| Operating Margin | -62.29% |
| Pretax Margin | -68.35% |
| Profit Margin | -73.02% |
| EBITDA Margin | -50.60% |
| EBIT Margin | -62.29% |
| FCF Margin | n/a |
Dividends & Yields
LabGenomics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.47% |
| Shareholder Yield | -0.47% |
| Earnings Yield | -67.06% |
| FCF Yield | -33.00% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 7, 2023. It was a forward split with a ratio of 2.
| Last Split Date | Aug 7, 2023 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
LabGenomics has an Altman Z-Score of 1.5 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.5 |
| Piotroski F-Score | 2 |